来自官方财务报表的收入、利润与现金流历史。
Tsumura & Co. engages in the production and sale of Kampo extract intermediates and granular Kampo formulations in Japan and internationally. The company offers products for female problems, proneness to fatigue, skin problems, gastrointestinal problems, obesity, constipation and hemorrhoids, as well as body aches, children's sickness, stress, urinary problems, and cold, cough, and nasal/throat inflammation symptoms. It is also involved in manufacturing and sales of prescription drugs and over-the-counter Kampo medicines.
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| 总收入 | JPY 192.6B | JPY 181.1B | JPY 150.8B | JPY 140.0B | — |
| 毛利 | JPY 91.5B | JPY 90.6B | JPY 68.8B | JPY 68.3B | — |
| 营业利润（EBIT） | JPY 35.2B | JPY 40.1B | JPY 20.0B | JPY 20.9B | — |
| 净利 | JPY 28.1B | JPY 32.4B | JPY 16.7B | JPY 16.5B | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 4540 交互式查看器。 /companies/us/4540
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms